Smith+Nephew is a global medical technology company founded in 1856, operating in more than 100 countries with over 18,000 employees. The company designs and manufactures technology focused on the repair, regeneration, and replacement of soft and hard tissue across three primary business units: Orthopaedics, Sports Medicine + ENT, and Advanced Wound Management. As a publicly traded company listed on both the London Stock Exchange (FTSE 100) and New York Stock Exchange, Smith+Nephew serves millions of patients annually through healthcare systems worldwide.
The company's robotics portfolio centers on the CORI Surgical System, a robotics-assisted surgery platform used in orthopaedic procedures. This system represents Smith+Nephew's entry into surgical robotics, a technical domain that intersects with their broader expertise in orthopaedic implants and surgical instrumentation. Beyond robotics, the company manufactures bioinductive implants such as the REGENETEN Bioinductive Implant for tissue repair and regeneration, as well as advanced wound care systems including PICO, a negative pressure wound therapy device. The company maintains integrated design and manufacturing capabilities for medical devices across these product lines.
Smith+Nephew's technical domains span medical device development with emphasis on orthopaedics, sports medicine, ENT procedures, and wound management technologies. The engineering work involves challenges in surgical robotics systems, implantable biomaterials, negative pressure therapy mechanisms, and the regulatory requirements inherent to medical device development. The company's headquarters are in the United Kingdom, with its origins tracing to a small pharmacy in Hull, England, though its current operations span a multinational footprint supporting clinical applications in diverse healthcare environments.
